GET DAILY SIGNALSMirum Pharmaceuticals (MIRM) +19.7% in 30 Days: Pipeline Momentum and Analyst Upgrades Drive the Rally
Key Takeaways
- Mirum Pharmaceuticals (MIRM) surged approximately 19.7% over the past 30 days, climbing from $101.00 on June 15 to $120.89 on July 14, 2026.
- The rally was fueled by positive pivotal Phase II data for zilurgisertib in fibrodysplasia ossificans progressiva (FOP) and the FDA's acceptance of the New Drug Application (NDA) under priority review.
- Multiple Wall Street analysts raised price targets, with the consensus 12-month target now standing at $143.40, implying additional upside potential.
- Strong institutional inflows underscored growing confidence, with several major funds increasing their MIRM positions during the first and second quarters.
- The stock has gained roughly 25% over the broader quarter, driven by pipeline momentum, commercial execution, and expanding analyst coverage.
Mirum Pharmaceuticals (MIRM): Company Snapshot and Rare Disease Focus
Mirum Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing therapies for rare liver and genetic diseases. Its commercial portfolio includes LIVMARLI (maralixibat), approved for cholestatic pruritus in patients with Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC); CHOLBAM (cholic acid) for bile-acid synthesis disorders; and CTEXLI (chenodiol) for cerebrotendinous xanthomatosis (CTX). The company's pipeline features volixibat in late-stage trials for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug for chronic hepatitis delta virus (HDV), zilurgisertib under FDA priority review for FOP, and MRM-3379 for Fragile X syndrome. With a market capitalization of approximately $7.4 billion, Mirum occupies a distinctive niche in the rare disease space, where high unmet medical need and limited competition create substantial commercial opportunities.
Stock Performance: 30-Day Surge and Quarterly Gains
Over the last 30 days, MIRM shares rallied from a closing price of $101.00 on June 15, 2026, to $120.89 on July 14, 2026 — a gain of approximately 19.7%. The stock reached an intra-period high of $130.00, marking a new 52-week peak, before experiencing modest profit-taking in subsequent sessions. Trading volume spiked notably during the rally, with several sessions exceeding 1.5 million shares, well above the daily average, indicating strong institutional participation. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Zooming out to the quarterly timeframe, the stock has risen roughly 25% from mid-April levels near $96.40. The advance was not linear; MIRM experienced a sharp pullback in mid-May from above $110 to the mid-$90s before buyers stepped in and drove the sustained recovery that defines the current trend. The 50-day moving average sits near $107, and the 200-day moving average is approximately $98, confirming a bullish intermediate and long-term technical posture.
Catalysts Behind the 30-Day Rally
The primary catalyst behind the 30-day surge was the announcement of positive pivotal Phase II data from Cohort 1 of the PROGRESS study evaluating zilurgisertib, an investigational oral ALK2 inhibitor, in patients with fibrodysplasia ossificans progressiva (FOP). The data demonstrated a meaningful reduction in new heterotopic ossification lesions and improvements across key secondary endpoints including lesion volume and disease flare activity. Shortly afterward, the FDA accepted the NDA for zilurgisertib under priority review, setting a PDUFA target action date of September 26, 2026.
Wall Street responded with a wave of bullish analyst actions. JPMorgan raised its price target from $115 to $125 with an Overweight rating. Royal Bank of Canada lifted its target from $142 to $148. Citizens JMP moved from $140 to $146, while H.C. Wainwright reiterated a Buy rating with a Street-high target of $185. Citi initiated coverage with a Buy rating and a $145 target. Morgan Stanley maintained a Buy at $150, and Wolfe Research launched coverage at $145. The average analyst price target reached $143.40, offering a compelling valuation argument.
Institutional flows reinforced the bullish sentiment. SEC filings revealed that Hillsdale Investment Management increased its MIRM stake by 25.4%, Emerald Advisers added 8.2%, and Principal Financial Group boosted its position by 81.2%. These moves signaled confidence from professional money managers. Insider selling — including CEO Christopher Peetz's sale of 20,000 shares at $122.27 under a pre-arranged 10b5-1 plan — attracted attention but did not derail momentum, as such transactions are typically planned well in advance.
Broader Quarterly Drivers and Commercial Progress
The broader quarterly advance reflects Mirum's evolution from a single-product rare disease company into a multi-franchise commercial organization with a maturing pipeline. First-quarter 2026 revenue reached $159.88 million, a 43.3% year-over-year increase that exceeded consensus estimates of $148.21 million, driven by expanding LIVMARLI adoption across approved indications. Although reported EPS of negative $13.43 reflected significant non-cash charges related to prior acquisitions, the underlying commercial revenue trajectory strengthened the investment thesis.
Pipeline progress across multiple programs sustained the narrative. Beyond zilurgisertib, volixibat continued advancing through pivotal studies in PSC and PBC, while brelovitug progressed in late-stage HDV development. The FDA's acceptance of zilurgisertib's NDA under priority review transformed the stock's risk profile by moving a high-value asset closer to potential commercialization. Expanding analyst coverage — with 15 firms now covering the stock and 14 issuing Buy-equivalent ratings — provided additional institutional validation throughout the quarter.
Exploring AI-Powered Trading Insights for Stocks Like MIRM
One tool I find useful for data-driven strategies is Tickeron's Trending AI Robots. It offers a curated view of top-performing AI-powered trading bots that trade across thousands of tickers, but only those demonstrating consistent performance and relevance appear in this featured section. The bots employ diverse strategies spanning various timeframes, technical patterns, and fundamental signals, enabling users to explore approaches that align with their individual trading preferences. Each bot's track record is transparently displayed with key performance metrics. Investors looking to complement their analysis with algorithm-driven insights can explore the Trending AI Robots section to identify strategies actively generating signals in the current market environment.
What Investors Should Watch Next
The most consequential near-term event for MIRM is the FDA's decision on zilurgisertib for FOP, expected by September 26, 2026. Approval would add a first-in-class therapy addressing an ultra-rare indication with no currently approved treatments, potentially opening a new revenue stream and reinforcing Mirum's rare disease franchise. The company's second-quarter earnings report, anticipated in early August, will provide updated commercial metrics for LIVMARLI, CHOLBAM, and CTEXLI, as well as pipeline timelines. Revenue growth trajectory, operating expense management, and any updates on volixibat's pivotal trial progress will be closely scrutinized. Broader macroeconomic factors — including interest rate expectations affecting biotechnology valuations, potential healthcare policy shifts, and sector rotation dynamics — remain relevant. Competitive developments in the rare cholestatic liver disease space, regulatory updates in ex-U.S. markets, and further institutional positioning disclosures will also shape the stock's direction in the months ahead.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MIRM sees its Stochastic Oscillator recovers from oversold territory
On October 19, 2026, the Stochastic Oscillator for MIRM moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 67 instances where the indicator left the oversold zone. In 60 of the 67 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MIRM's RSI Indicator exited the oversold zone, 11 of 13 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for MIRM just turned positive on October 12, 2026. Looking at past instances where MIRM's MACD turned positive, the stock continued to rise in 35 of 46 cases over the following month. The odds of a continued upward trend are 76%.
Following a +6.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where MIRM advanced for three days, in 235 of 312 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MIRM as a result. In 73 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.
The 50-day moving average for MIRM moved below the 200-day moving average on October 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MIRM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
The Aroon Indicator for MIRM entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: MIRM's P/B Ratio (-518.797) is very low in comparison to the industry average of (3.037). P/E Ratio (-5.914) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (8.842) is also within normal values, averaging (439.237).
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 36 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. MIRM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company. which focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases.
Industry Biotechnology
Advertisement